Results 161 to 170 of about 10,952 (242)

The intersection between psychedelics and schizophrenia spectrum disorders: Reevaluating risk and therapeutic potential. [PDF]

J Psychopharmacol
Brar PS, Price RB, Ross S, Tofighi B, Sarpal DK.   +4 more
europepmc   +1 more source

Editorial: Emerging treatment approaches for substance use disorders. [PDF]

Front Psychiatry
Martinez Garza D, Blokhin IO, Brett J, Salloum I.   +3 more
europepmc   +1 more source

Serotonergic psychedelics induce distinct patterns of metabolic activity and covariance within biologically informed rat brain networks. [PDF]

Nat Commun
Gudmundsen F, Czurylo J, Rijsketic DR, Vo CT, Fortunato J, Jessen NS, Woodruff S, Baun C, Herth MM, Shalgunov V, Heifets BD, Fisher PM, Palner M.   +12 more
europepmc   +1 more source

Novel Tetrahydropyridinyl-6,6-Bicyclic Compounds as 5‑HT2A Receptor Agonists for Treating Depression, Anxiety, Substance Abuse, and Headaches. [PDF]

ACS Med Chem Lett
Sabnis RW, Sabnis AR.
europepmc   +1 more source

Psychedelics in Mental Health: Opportunities and Challenges. [PDF]

Brain Behav
Oestreich LKL, Rieser NM.
europepmc   +1 more source

Mechanistic insights toward dissociating therapeutic from psychedelic effects: bridging the gap between psychedelic research and mental health care. [PDF]

Transl Psychiatry
Pettorruso M, d'Andrea G, Inserra A, Cavallotto C, Censi S, Billard E, Di Stefano A, De Risio L, Tullo MG, D'Addario C, Di Lorenzo G, Wise RG, Sensi SL, Zoratto F, Martinotti G.   +14 more
europepmc   +1 more source

Novel pharmacotherapies for opioid use disorder and opioid withdrawal. [PDF]

Front Psychiatry
Shen MR, Owusu-Boaitey K, Murphy ZD, Rains AN, Wang PR, Zhou DW, Suzuki J.   +6 more
europepmc   +1 more source

Computational spirits: a neuroscientific account of psychedelic entity encounters. [PDF]

Neurosci Conscious
Mago J, Deane G, Sandved-Smith L, Safron A, Timmermann C, Ramstead M, Dupuis D, Carhart-Harris R, Greenway KT, Lifshitz M.   +9 more
europepmc   +1 more source

Implications of Potential US FDA Approval of Psychedelics or Psychedelic-Adjacents Such as Ibogaine for Pharmacy in Japan. [PDF]

Cureus
Raffa RB.
europepmc   +1 more source